This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q74460248
rdf:type
wikibase:Item
schema:description
scientific article published on 01 August 2001 article scientifique publié en 2001 im August 2001 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu n'agostu de 2001 наукова стаття, опублікована в серпні 2001 wetenschappelijk artikel
p:P577
wds:Q74460248-2BDA1D25-5464-4ACB-899D-E0AD0EC65D4A
wdt:P577
2001-08-01T00:00:00Z
p:P2888
wds:Q74460248-F17C17E2-065F-4259-A26A-B65F562EB387
wdt:P2888
n10:sj.bmt.1703137
p:P2860
wds:Q74460248-80152981-8D8E-4A8C-822F-0F81198FECC5 wds:Q74460248-70BE53D3-C51A-47C5-A303-7585D99F1D07 wds:Q74460248-71A74F66-51D6-4FAC-BA6F-0371A4573503 wds:Q74460248-94FC29BB-BF5C-4A1A-BE17-AA0220A16D5E wds:Q74460248-9659D50E-85A0-4AE1-81B4-0B6CE8791F1B wds:Q74460248-9FC459AA-288B-4CE3-971E-D78AFE65563D wds:Q74460248-90931C01-A766-4721-9BB9-6D0B2B32C2BD wds:Q74460248-1859F3F3-1F96-452F-94E6-119CFC6E99F8 wds:Q74460248-073513BB-34E9-4C65-A64F-D877C9675C3B wds:Q74460248-62A5E33C-F543-4D35-AEAA-007E0BFBF2D6 wds:Q74460248-3EA54940-0F2D-4D6C-8476-47114B4341A7 wds:Q74460248-4377556F-BAF1-4146-AEAC-C31C83D5802F wds:Q74460248-4E989062-FEAC-4C0A-8773-BDD5D36476B1 wds:Q74460248-CA90D841-BD98-4F15-97AB-D14AD257B8EB wds:Q74460248-CFDD5A8E-62C2-4533-8B03-27B4B8D0FEE6 wds:Q74460248-D1D8AEA4-EFAF-46E3-8692-799D6EFD944F wds:Q74460248-ECE16A17-15FC-4FC5-817F-5BACE18003DB wds:Q74460248-F6778BAC-C79E-423F-B35C-AC7831E764E1 wds:Q74460248-D6BFA089-1F05-40AC-83CB-62D01F194600 wds:Q74460248-E89B595F-54AE-4FA6-B4E0-3244802D0B27
wdt:P2860
wd:Q71832943 wd:Q47799719 wd:Q77816227 wd:Q33498955 wd:Q47976246 wd:Q71558484 wd:Q71725004 wd:Q47989759 wd:Q33647747 wd:Q67532474 wd:Q33640068 wd:Q33328853 wd:Q77101787 wd:Q73358706 wd:Q71020091 wd:Q54053154 wd:Q77816213 wd:Q74570859 wd:Q50970785 wd:Q49158499
p:P2093
wds:Q74460248-84C4BBA2-1BBC-4370-8738-D0B70A3C7560 wds:Q74460248-A88915D8-DDD9-4B4E-BFC2-E0AB20300848 wds:Q74460248-B7D9905C-4463-4AEF-B3DA-ED9CF3E17371 wds:Q74460248-AD1C9DD8-8C66-4658-B368-B1B7FF49D0B7 wds:Q74460248-B572D781-351A-4E1F-8DB7-87ACC2BB10B4 wds:Q74460248-C40A017C-C859-4EC7-86B3-52AADDD2524F wds:Q74460248-D7A4C29C-85F0-4459-88BC-845AC4E266E1 wds:Q74460248-D32E65FA-1AC6-4CAF-98C3-D2BAB01E8BD8 wds:Q74460248-F8044114-637D-414A-A45D-DCBE59C2B27A wds:Q74460248-FB6D019E-E25D-4B7F-98EC-918E4B8ADBC6 wds:Q74460248-14EE91F7-83D5-4E8D-8027-FB9275465133 wds:Q74460248-5B07809D-93D0-405F-9F61-6B1A77F7EA6A wds:Q74460248-56558F72-BCFC-4BD1-8C87-73531DAE6855 wds:Q74460248-7F1B45E9-66CD-4914-B48E-7181F1191E47
wdt:P2093
Parthasarathy M Stiff P Mandalam RK Chen B Preti R LeMaistre CF Jennis AA Bachier C Armstrong RD Bayer R Pecora AL Smith AK Douville J Goldberg SL
rdfs:label
A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
skos:prefLabel
A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
schema:name
A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
p:P1476
wds:Q74460248-C07181EC-0C78-4AE0-AF99-A9E5AA6FD685
wdt:P1476
A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation
p:P304
wds:Q74460248-7314D10F-627F-44E3-AF53-7D016124CB5D
wdt:P304
295-303
p:P31
wds:Q74460248-F3EC70E4-DBFA-4BEE-A50E-58C1909A54BE
wdt:P31
wd:Q13442814
p:P921
wds:Q74460248-92806E24-0696-480D-BB83-83FBC77ADB4C wds:Q74460248-92C0B7D1-3457-4946-A897-E4065D213C1E
wdt:P921
wd:Q65592366 wd:Q42824440
p:P698
wds:Q74460248-4890718E-F70B-42D5-B821-C7E97C55C3B9
wdtn:P698
n12:11535999
wdt:P698
11535999
p:P1433
wds:Q74460248-752BFB29-A5CE-430D-9632-A6FA1589F9BB
wdt:P1433
wd:Q4941523
p:P433
wds:Q74460248-53852850-7889-4544-B491-4E5432EA9A2C
p:P478
wds:Q74460248-6C2AD860-DF53-4456-B839-304AF0D462D7
wdt:P433
3
wdt:P478
28
p:P356
wds:Q74460248-385FDCED-0112-4B15-AD40-5E83697B32CB
wdtn:P356
n8:SJ.BMT.1703137
wdt:P356
10.1038/SJ.BMT.1703137
p:P6179
wds:Q74460248-721E7EEE-9618-41E9-837A-A2D12A925249
wdt:P6179
1026345908